Trixeo Aerosphere

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification [1] issued on	Commission Decision Issued [2] / amended on	Product Information affected [3]	Summary
WS/2780	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Type II var - B.II.a.3.b.2 Changes in the qualitative and quantitative composition of the	24/07/2025		SmPC, Labelling and PL	SmPC new text: • Section 4.6 – Pregnancy There is no experience with the use of the propellant HFO 1234ze(E) during human pregnancy or lactation. However, studies on the effect of HFO 1234ze(E) on the reproductive function and embryofoetal development in animals revealed

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

	finished product to replace the propellant HFA-134a with HFO-1234ze(E). The change is reflected in the PI and it is supported by non clinical and clinical data. B.II.a.3.b.2 - Changes in the composition (excipients) of the finished product - Other excipients - Qualitative or quantitative changes in one or more excipients that may have a significant impact on the safety, quality or efficacy of the product				no clinically relevant adverse effects. • Section 5.2 - Effect of a spacer The use of this medicinal product with the Aerochamber Plus Flow-Vu spacer in healthy volunteers showed no increase in total systemic exposure (as measured by AUC0-t) to budesonide, glycopyrronium or formoterol. An increase in Cmax was observed with the use of spacer for budesonide, glycopyrronium and formoterol, by 27%, 88% and 50%, respectively. Subjects who had low exposure without a spacer (likely due to poor inhalation technique) had a higher increase in total systemic exposure when using a spacer. • Section 6.1 - The excipient norflurane has been replaced with HFO 1234ze(E) • Section 6.3 – The shelf life has been updated from 3 years to 2 years. For more information, please refer to the Summary of Product Characteristics. The labelling and Package Leaflet have been updated accordingly.
Variation type IB / EMA/VR/0000264393	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.				
Renewal - 5 year / EMA/R/0000245136	- Renewal - Accepted	19/06/2025	14/08/2025	SmPC, Annex II, Labelling and PL	Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Trixeo Aerosphere in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. The product information was updated in accordance with the latest QRD template and section 5.1 of the SmPC was updated with a clarifying statement.

PSUR / EMA/PSUR/0000257877	Periodic Safety Update EU Single assessment - formoterol fumarate dihydrate / glycopyrronium bromide / budesonide				Maintenance
PSUSA/10908/202406	Periodic Safety Update EU Single assessment - formoterol fumarate dihydrate / glycopyrronium bromide / budesonide	16/01/2025	n/a		PRAC Recommendation - maintenance
N/0023	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	05/11/2024	14/08/2025	Labelling and PL	
IG/1789	A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)	27/09/2024	n/a		
IG/1777/G	This was an application for a group of variations. B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier	25/07/2024	n/a		
WS/2642/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008.	25/07/2024	n/a		

	B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.4.d - Change in the batch size (including batch size ranges) of the finished product - The change relates to all other pharmaceutical forms manufactured by complex manufacturing processes				
PSUSA/10908/202312	Periodic Safety Update EU Single assessment - formoterol fumarate dihydrate / glycopyrronium bromide / budesonide	11/07/2024	n/a		PRAC Recommendation - maintenance
WS/2595/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.c.1.c - Change in the specification parameters and/or limits of an excipient - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter) B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition)	08/02/2024	n/a		

PSUSA/10908/202306	Periodic Safety Update EU Single assessment - formoterol fumarate dihydrate / glycopyrronium bromide / budesonide	11/01/2024	n/a		PRAC Recommendation - maintenance
N/0017	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	23/11/2023	12/08/2024	PL	
WS/2521	This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	19/10/2023	n/a		
WS/2457/G	This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) B.II.d.1.g - Change in the specification parameters and/or limits of the finished product - Addition or replacement (excluding biological or immunological product) of a specification parameter wit its corresponding test method as a result of a safety or quality issue B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range	31/08/2023	12/08/2024	SmPC	The SmPC section 6.3 Annex II has been updated as follows: Shelf-life 3 years

	A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient				
PSUSA/10908/202212	Periodic Safety Update EU Single assessment - formoterol fumarate dihydrate / glycopyrronium bromide / budesonide	06/07/2023	n/a		PRAC Recommendation - maintenance
IG/1603/G	This was an application for a group of variations. B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to	14/04/2023	n/a		

	the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer				
PSUSA/10908/202206	Periodic Safety Update EU Single assessment - formoterol fumarate dihydrate / glycopyrronium bromide / budesonide	12/01/2023	n/a		PRAC Recommendation - maintenance
IG/1542	B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer	16/09/2022	n/a		
PSUSA/10908/202112	Periodic Safety Update EU Single assessment - formoterol fumarate dihydrate / glycopyrronium bromide / budesonide	07/07/2022	n/a		PRAC Recommendation - maintenance
IA/0008	A.7 - Administrative change - Deletion of manufacturing sites	19/05/2022	15/05/2023	Annex II and PL	
PSUSA/10908/202106	Periodic Safety Update EU Single assessment - formoterol fumarate dihydrate / glycopyrronium bromide / budesonide	13/01/2022	n/a		PRAC Recommendation - maintenance
IB/0004/G	This was an application for a group of variations. B.II.e.5.b - Change in pack size of the finished product - Deletion of a pack size(s) B.II.g.5.b - Implementation of changes foreseen in an approved change management protocol -	01/10/2021	24/06/2022	SmPC, Labelling and PL	

	Requires further supporting data				
IA/0006	B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer	22/09/2021	n/a		
PSUSA/10908/202012	Periodic Safety Update EU Single assessment - formoterol fumarate dihydrate / glycopyrronium bromide / budesonide	08/07/2021	n/a		PRAC Recommendation - maintenance
IAIN/0001/G	This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	17/02/2021	24/06/2022	SmPC, Annex II and PL	